1. Expression of leukemia inhibitory factor in the endometrium in abnormal uterine cavities during the implantation window 
Ei Hasegawa, M.D., Hiroe Ito, M.D., Ph.D., Fumiko Hasegawa, M.D., Keiko Hatano, M.D., Masahiro Kazuka, M.D., Ph.D., Saburo Usuda, M.D., Ph.D., Keiichi Isaka, M.D., Ph.D. 
Fertility and Sterility 
Volume 97, Issue 4, Pages (April 2012)
DOI: /j.fertnstert
Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Endometrial leukemia inhibitory factor (LIF), interleukin-11 (IL-11), and IL-6ST mRNA expression. The menstrual cycle in the control group was divided into four phases: P.P. (proliferative phase), O.P., (ovulative phase), M-S.P., (midsecretory phase), and L-S.P., (late secretory phase). ∗P=.05; ∗∗P<.05.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

3. Figure 2
(A) LIF, IL-11, and IL-6ST/gp130 mRNA expressions between the abnormal uterine cavity group and the control group in the midsecretory phase. ∗P<.001. (B) LIF mRNA expression between the control group and the abnormal uterine cavity group. The latter was then further divided into patients with a submucosal myoma or those with an endometrial polyp, and LIF mRNA expression was compared with that in the control group at the midsecretory phase. ∗P=.0043; ∗∗P<.001. Abbreviations as in Figure 1.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions